Comparative study of intravenous hydralazine and labetalol in severe hypertensive disorders of pregnancy

Simple item page
dc.contributor.authorKumari, Anupmaen_US
dc.contributor.authorRohatgi, Renuen_US
dc.contributor.authorSingh, Amritaen_US
dc.contributor.authorKumar, Rajen_US
dc.date.accessioned2020-10-16T08:02:17Z
dc.date.available2020-10-16T08:02:17Z
dc.date.issued2020-02
dc.description.abstractBackground: Hypertensive disorders of pregnancy are among the most common medical complications of pregnancy and major cause of maternal, fetal and neonatal morbidity and mortality. The purpose of this study was to compare the efficacy and safety of intravenous hydralazine and labetalol for management of severe hypertensive disorders of pregnancy.Methods: This prospective study was conducted among 100 women admitted with SBP ≥ 160 or DBP ≥ 110 mmHg or both. Patients were divided into 2 groups randomly: labetalol and hydralazine group.Results: Majority of patients (38%) were in the age group of 21-25 years and primigravida (52%). There was more significant decrease in the systolic, diastolic and mean arterial blood pressure at the end of 15 and 30 minutes in labetalol group. Labetalol required fewer doses as compared to hydralazine to achieve the target blood pressure (average 1.95 versus 3.1). Total numbers of term deliveries were 19 (38%) in hydralazine group and 16 (32%) in labetalol group. Pre-term deliveries in hydralazine and labetalol group were 14 (28%) and 15 (30%) respectively. Headache was significantly more common in hydralazine treated patients than labetalol group.Conclusions: Both hydralazine and labetalol were effective and well-tolerated in the treatment of severe hypertensive disorders of pregnancy. Labetalol may be preferred because it was more effective in lowering the systolic blood pressure, diastolic blood pressure and mean arterial pressure to achieve target levels with less number of doses.en_US
dc.identifier.affiliationsDepartment of Obstetrics and Gynecology, N. M. C. H., Patna, Bihar, Indiaen_US
dc.identifier.affiliationsDepartment of Obstetrics and Gynecology, L. H. M. C., New Delhi, Indiaen_US
dc.identifier.affiliationsDepartment of Orthopaedics, RIMS, Ranchi, Jharkhand, Indiaen_US
dc.identifier.citationKumari Anupma, Rohatgi Renu, Singh Amrita, Kumar Raj. Comparative study of intravenous hydralazine and labetalol in severe hypertensive disorders of pregnancy. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2020 Feb; 9(2): 675-681en_US
dc.identifier.issn2320-1770
dc.identifier.issn2320-1789
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/207422
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber2en_US
dc.relation.volume9en_US
dc.source.urihttps://dx.doi.org/10.18203/2320-1770.ijrcog20200357en_US
dc.subjectHydralazineen_US
dc.subjectHypertensive disorders of pregnancyen_US
dc.subjectLabetalolen_US
dc.subjectMean arterial blood pressuresen_US
dc.titleComparative study of intravenous hydralazine and labetalol in severe hypertensive disorders of pregnancyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijrcog2020v9n2p675.pdf
Size:
188.33 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Reproduction, Contraception, Obstetrics and Gynecology